The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Affymetrix, Inc. announced the completion of the GeneChip brand Smallpox Resequencing Array Set - seven smallpox arrays that enable resequencing of the entire smallpox genome. The arrays, developed in collaboration with the Centers for Disease Control and Prevention (CDC), contain genomic sequence common to all strains of smallpox, as well as variant DNA from different smallpox isolates. The Array Set will be used to identify and catalog hundreds of different smallpox strains within the World Health Organization collection maintained at the CDC and will also help researchers differentiate smallpox from other orthopox viruses like monkeypox or cowpox. Agilent Technologies Inc. launched its whole human genome microarray compatible with major 1" x 3" microarray scanners. The whole human genome microarray represents approximately 41,000 genes and transcripts. Applied Biosystems introduced two new real-time PCR systems for the detection and quantification of nucleic acid sequences. The Applied Biosystems 7300 Real-Time PCR System and the Applied Biosystems 7500 Real-Time PCR System combine thermal cycling, fluorescence detection, and application-specific software. Caliper Life Sciences, Inc. introduced the LabChip 3000 Drug Discovery System - the latest addition to the company's suite of LabChip Microfluidic Systems. The automated system performs unattended biochemical and cell-based screening assays using Caliper's microfluidic chips. The LabChip 3000 Drug Discovery System is an updated and improved version of the Caliper 250 system. Third Wave Technologies Inc. released its Invader CYP450 2D6 analysis panel, providing clinical trial laboratories with access to pharmacogenetic assays for the 2D6 gene. The 2D6 enzyme metabolizes approximately 25% of all therapeutic drugs; genetic changes in this enzyme are the best characterized of all the drug-metabolizing enzymes. These changes can cause a seven- to 10-fold decrease in the body's ability to clear these and other drugs. Approximately 10% of Caucasians lack any 2D6 activity due to genetic variation. Third Wave also announced the launch of its Invader analyte-specific reagents (ASRs) for prenatal chromosomal analysis under an early-adopter program. The company will work with key opinion leaders to determine the best applications for its new approach in the chromosomal analysis market, which includes prenatal, oncological, and other testing. Third Wave intends to broadly launch Invader ASRs for chromosomal analysis during the fourth quarter of 2004.
Molecular Biology - January 2004
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: March 09, 2004 |